With the growing body of knowledge on the contribution of efflux activity to Mycobacterium tuberculosis drug resistance, increased attention has been given to the use of efflux inhibitors as adjuvants of tuberculosis therapy. Here, we investigated how efflux activity modulates the levels of efflux between monoresistant and multi-and extensively drug resistant (M/XDR) M. tuberculosis clinical isolates. The strains were characterized by antibiotic susceptibility testing in the presence/absence of efflux inhibitors, molecular typing, and genetic analysis of drug-resistance-associated genes. Efflux activity was quantified by real-time fluorometry. The results demonstrated that all the M. tuberculosis clinical strains, susceptible or resistant, presented a faster, rapid, and non-specific efflux-mediated short-term response to drugs. The synergism assays demonstrated that the efflux inhibitors were more effective in reducing the resistance levels in the M/XDR strains than in the monoresistant strains. This indicated that M/XDR strains presented a more prolonged response to drugs mediated by efflux compared to the monoresistant strains, but both maintain it as a long-term stress response. This work shows that efflux activity modulates the levels of drug resistance between monoresistant and M/XDR M. tuberculosis clinical strains, allowing the bacteria to survive in the presence of noxious compounds.
Introduction
Tuberculosis (TB) is a major public health problem worldwide, accounting for an estimated 10.4 million new cases and 1.3 million deaths in 2016 [1] . Despite worldwide efforts to reduce the global burden of tuberculosis, multidrug resistant (MDR) and extensively drug resistant (XDR) tuberculosis (continue to increase, leaving very limited therapeutic options for these patients. The emergence of MDR (simultaneous resistance to isoniazid and rifampicin) and XDR (MDR with additional resistance to second-line injectables and fluoroquinolones) Mycobacterium tuberculosis has become a major public health concern worldwide. There was an estimate of 490,000 new MDRTB cases with approximately 200,000 deaths in 2016. Among these, 6.2% were anticipated to be XDRTB cases [1] . or both in MDR and XDR M. tuberculosis strains overexpressing efflux pumps than in the monoresistant strains [18] . This data seems to indicate that the efflux activity may be strain-dependent and the efflux inhibitors exert their greatest effect on strains with increased efflux activity. The purpose of the present work is to study the correlation between the effect of efflux inhibitors and the genetic background, drug resistance profile and efflux activity in clinical strains of M. tuberculosis in order to describe how the efflux activity modulates the levels of resistance in strains presenting different drug-resistance associated mutations and genetic backgrounds. Understanding the dynamic underlying bacterial antibiotic-induced systems could provide a route for new chemotherapeutic approaches.
Results

Characterization of the M. tuberculosis Strains According to Their Efflux Capacity
The 18 M. tuberculosis strains were firstly characterized according to their efflux capacity using a fluorometric method that detects in real-time the accumulation and efflux of ethidium bromide in bacterial cells loaded with this fluorophore [19, 31, 32] . For this purpose, we selected a panel of susceptible, monoresistant, and M/XDR M. tuberculosis clinical isolates. These strains were chosen in order to include the most prevalent mutations associated with resistance to isoniazid and rifampicin. As controls, we selected three pan-susceptible M. tuberculosis strains and the H37Rv reference strain (Table 1) . Figure 1 illustrates the results of the ethidium bromide fluorometric assays and the parameters used to characterize the efflux capacity of the 18 M. tuberculosis strains, giving as example the results obtained for strain H37Rv. [19, 32] ; (C) efflux rate constant, or K value, and the tefflux50% that corresponds to the time required for the cells to extrude half of the preloaded dye; the efflux of ethidium bromide is initiated at t0 by the addition of 0.4% glucose and is 50% complete at tefflux50%. [19, 32] ; (C) efflux rate constant, or K value, and the t efflux50% that corresponds to the time required for the cells to extrude half of the preloaded dye; the efflux of ethidium bromide is initiated at t 0 by the addition of 0.4% glucose and is 50% complete at t efflux50% .
Initially we determined the Span EtBr index as a measure of the capacity of each strain to accumulate ethidium bromide. This value corresponds to the difference between the ethidium bromide fluorescence values at t 0 of the highest concentration tested (Y hc ) and the fluorescence value at t 0 of the equilibrium concentration of ethidium bromide (Y eqc ) (Figure 1 ). High Span EtBr indexes indicated increased capacity to accumulate ethidium bromide. The equilibrium concentration is the concentration where the uptake of ethidium bromide by the cell equals its efflux and corresponds to the first concentration that gives no more than 10 units of fluorescence at the end of the 60 min of the accumulation assay (indicated by the red arrow on the graph). The results obtained for the strains tested are shown in Table 2 . The accumulation of ethidium bromide for the M. tuberculosis strains took place at concentrations above 0.5 µg/mL for Mtb#3, Mtb#8, Mtb#11, and Mtb#12; 0.25 µg/mL for H37Rv, Mtb#1, Mtb#4, Mtb#6, Mtb#7, Mtb#13, Mtb#14, Mtb#16, and Mtb#17; and 0.125 µg/mL for Mtb#2, Mtb#5, and Mtb#9. Analysing the data presented in the Table 2 , we can observe that the susceptible strains presented higher Span EtBr values than the drug resistant strains, which is indicative of an increased accumulation of ethidium bromide at higher concentrations (lesser ability to efflux). Concerning the drug resistant strains, there was no significant difference on the Span EtBr values between the monoresistant strains and the M/XDR strains ( Table 2) . These results showed that the drug resistant strains (monoresistant and M/XDR) can handle higher concentrations of ethidium bromide than the susceptible ones having a higher efflux capacity.
Next, we compared the rate of accumulation of ethidium bromide in the presence of the efflux inhibitors as an indirect method to evaluate the efflux capacity of these strains (Table 2; Figure 2A ). For this purpose, we selected verapamil and thioridazine, two well-known efflux inhibitors of M. tuberculosis efflux systems [7, 17, 19, 22, 23, 33] , and determined the RFF indexes. The RFF index is measure of how effective a compound is on the inhibition of ethidium bromide efflux (at a given concentration) by comparison of the final fluorescence at the last time point (60 min) of the treated cells with the cells in presence of only ethidium bromide. At the same time, high levels of inhibition, or high RFF values, indicate higher efflux activity of the strain and vice versa. As showed in Table 2 , verapamil promoted the highest levels of accumulation of ethidium bromide (RFF > 1) in 14 out of 16 of the strains tested. Thioridazine showed to be less potent in the inhibition of ethidium bromide efflux than verapamil as previously described [17, 33] . These results indicated that all strains have active efflux systems that can be inhibited by verapamil and, in less extent, by thioridazine.
Finally, to directly compare the efflux capacity of each strain, we further determined the efflux rate constant, or K value, and the t efflux50% that corresponds to the time required for the cells to extrude half of the preloaded dye ( Table 2 ). To preload the cells with ethidium bromide, we selected verapamil. Shown in Figure 2B are the results for selected strains on each of the drug resistance categories. The efflux rate constants obtained for the 14 strains, whose efflux activity could be inhibited by verapamil at high levels (RFF > 1), varied between 0.07 and 0.14. For the two strains with reduced efflux activity, Mtb#3 and Mtb#12, the efflux rate constants were 0.06 and 0.05, respectively.
Concordantly, these strains were the ones that showed the slowest efflux rates as they took more time to extrude half of the preloaded dye; strain Mtb#3 took 11.98 min and Mtb#12 took 14.06 min. On the other hand, the t efflux50% of the remaining strains was between 4.39 min and 8.95 min, where Mtb#8 had the lowest t efflux50% and Mtb#4 had the higher t efflux50% . No correlation could be observed between the different drug susceptibility profiles of the strains tested and the effect of both compounds on the ethidium bromide efflux inhibition confirming the results obtained on the ethidium bromide accumulation assays.
Overall, the results showed that (i) all strains presented efflux activity as a short-term stress response to drugs, and (ii) the drug resistant strains presented increased capacity to handle higher concentrations of toxic compounds, in this case, ethidium bromide, when compared with the susceptible strains, revealing an enhanced efflux capacity independently of their resistance phenotype. 
Effect of Efflux Inhibitors on the Resistance Levels to Rifampicin and Isoniazid
The MICs of the antibiotics and the efflux inhibitors for the M. tuberculosis strains included in this study are summarized in Table 1 . All the strains carried mutations in katG or inhA genes that have been described to be involved in the resistance to isoniazid, mutations in the rpoB gene which are associated with resistance to rifampicin, or both. The MICs of isoniazid for the strains presenting the mutation S315T in katG are between 10 and 20 µg/mL contrasting with the MICs presented by strains with mutations in inhA promotor (0.4 µg/mL) or inhA promotor plus ORF (Open Reading Frame) mutations (3 µg/mL). Regarding rifampicin, the strains with mutations in rpoB presented MICs between 20 µg/mL and 640 µg/mL. The MICs of both efflux inhibitors remained practically unchanged among all strains (one dilution noted).
Subsequently, the effect of verapamil and thioridazine on the susceptibility levels of these strains was evaluated (Table 3) . Verapamil increased the susceptibility to isoniazid in 8/11 strains and to rifampicin in 8/13 strains. In both cases, all the strains were at least MDR. Thioridazine showed a weaker effect, increasing the susceptibility to isoniazid in 5/11 strains and to rifampicin in 3/13 strains, all of them MDR. Comparing the data gathered for the monoresistant strains with the data of the MDR strains, it was noticed that verapamil and thioridazine were more effective in reducing the resistance levels of the M/XDR strains than of the monoresistant strains. This data indicated that the M/XDR strains presented a more prolonged response to drugs mediated by efflux as observed by the effect of verapamil on the susceptibility levels of isoniazid and rifampicin of these strains. Suscep.
INH, isoniazid; MDR, multidrug resistant; RIF, rifampicin; XDR, extensively drug resistant; VP, verapamil; TZ, thioridazine; suscep or S, susceptible; R, resistant; MIC, minimum inhibitory concentration. The lowest concentration of antibiotic tested corresponded to the critical concentration of each drug; the highest concentration tested was the one that defines high-level resistance according to the qDST procedure (see Material and Methods for details). Highlighted in red-bold type letter are the changes in the susceptibility (R to S) of the strain to the respective antibiotic at the concentration tested in the presence of the efflux inhibitor. -, not tested.
Nevertheless, although the resistance levels could not be reduced in the monoresistant strains, a synergistic effect was observed. The inhibition of growth of the monoresistant strains in presence of isoniazid or rifampicin in combination with the inhibitors showed a delay of 1 to 3 days between the tube containing the antibiotic plus the efflux inhibitor and the tube containing only the antibiotic (data not shown). The synergistic effect depended on the drug combination and the concentration of antibiotics tested, and demonstrates the existence of efflux activity in these strains but at lower levels compared to the M/XDR strains.
Analysing the data collected in Tables 1-3 , no correlation could be found between the genotype and the efflux activity of these strains.
Discussion
With the growing body of knowledge about the contribution of efflux activity to M. tuberculosis drug resistance, increased attention has been given to the use of efflux inhibitors as adjuvants of tuberculosis therapy [7, 8, 34] . In previous works, we showed that M. tuberculosis drug resistance levels are a balance between the presence of a mutation in the genes coding the drug target and active efflux [18] . We observed that strains presenting the same mutation conferring antibiotic resistance had different MICs and that the different resistance levels found could be reduced by efflux inhibitors. Although full susceptibility was not restored, the existence of a broad-spectrum synergistic interaction between antibiotics and efflux inhibitors was shown. However, we also noticed that the efflux inhibitors tested were significantly more effective against the M/XDR strains once compared with their monoresistant counterparts. An evident question posed by these results is why the efflux inhibitors are more effective on M/XDR strains. We hypothesized that the efficacy of the efflux inhibitors could be strain-dependent, i.e., it may depend on the (i) genetic background or (ii) type of mutation in the genes associated with resistance. To answer this question, in this study we investigated the effect of the efflux inhibitors verapamil and thioridazine on the efflux levels of a panel of M. tuberculosis clinical strains susceptible, isoniazid and rifampicin monoresistant, and M/XDR, in order to describe how the efflux activity modulates the levels of resistance in strains presenting different phylogenetic lineages and drug-resistance associated mutations.
The strains selected were the M. tuberculosis H37Rv, a worldwide used laboratory reference strain fully susceptible to the first-and second-line antibiotics, and a panel of 17 clinical strains differing on their phylogenetic origins, drug susceptibilities, and drug resistance associated mutations. Firstly, we characterized all the M. tuberculosis strains according to their efflux capacity by real-time fluorometry to analyse the short-term efflux-mediated responses to the presence of toxic compounds measuring the cells response via efflux of ethidium bromide. With this method, we detected and measured the efflux activity in all strains. This activity could be inhibited in the presence of verapamil, and less efficiently by thioridazine, regardless of the phenotype or genotype of the strain in study. The efflux assays clearly demonstrated that all the clinical strains, susceptible or resistant, presented a faster, very rapid, and non-specific efflux-mediated short-term response, when compared with the drug-naïve laboratory strain H37Rv, allowing the cells to cope in the presence of toxic compounds, as previous seen on laboratory efflux-induced strains [19] .
Concomitantly, the determination of the MICs of the antibiotics in the presence of the efflux inhibitors provided information regarding the efflux-mediated long-term response of the cells to the presence of noxious compounds, like ethidium bromide or antibiotics. Verapamil and thioridazine were able to reduce the resistance levels of isoniazid, rifampicin, or both in the M/XDR strains, and in particular it was possible to reverse the resistance to rifampicin in one of the MDR strains (Mtb#10). Interestingly, the same kind of results were not observed for the monoresistant strains. No reduction of the MICs in the presence of the efflux inhibitors was observed for the rifampicin or isoniazid monoresistant strains. Despite the absence of a reduction in the antibiotic resistance levels in the presence of the efflux inhibitors, a synergic effect between the efflux inhibitors and the antibiotics was noted through the evaluation of the delay in the time to detection (TTD) of growth, demonstrating some positive drug interaction, as expected by the presence of active efflux systems in these strains, as we have highlighted before. Efflux activity in the monoresistant strains occurs at lower levels compared to the M/XDR strains but both maintain it as a long-term stress response to drugs. Clearly, in the M/XDR strains this activity is increased, contributes to an overall high-level resistance to isoniazid and rifampicin, and can be reduced by the efflux inhibitors. These findings provide further evidence on the role of efflux as a global stress response in M. tuberculosis and corroborate the previous notion that M. tuberculosis clinical strains are primed to efflux toxic compounds [19] .
Moreover, the data obtained showed that the efflux activity and the effect of the efflux inhibitors does not depend on the strain genetic background and mutation(s) associated with drug resistance. The rifampicin resistance levels were reduced from 320 µg/mL to 20 µg/mL in four M/XDR strains harbouring the S531L rpoB mutation but not in the two rifampicin monoresistant strains presenting the same mutation. Also, the rifampicin resistance of the MDR strain Mtb#10, presenting the mutation H526Y on rpoB, was reversed from 20 µg/mL to 1 µg/mL in the presence of verapamil and thioridazine, but not in the rifampicin monoresistant strain (Mtb#6) that carried the same mutation. The same results were observed for the C-15T mutation on the inhA promoter between the M/XDR strains and the isoniazid monoresistant strain presenting the same mutation. Overall, these results are in concordance with those obtained with the real-time fluorometry assays (evaluation of the short-term efflux response), where it was shown that the efflux activity and the effect of the efflux inhibitors on this activity is independent on the drug-resistant associated mutations of the strains, but with the M/XDR strains recording higher levels of efflux activity.
Mutations such as the S315T in katG, C-15T in inhA promoter, and S531L in rpoB are predominant in M. tuberculosis clinical isolates and have been associated with successful transmission [35] [36] [37] . These mutations are the most frequently found in clinical isolates [38] , meaning that the M. tuberculosis population within the host may be undergoing adaptive evolution to improve bacterial fitness and efflux contribute for their survival and epidemiological success.
Materials and Methods
M. tuberculosis Strains
The strains studied are described in Table 1 . These strains are part of the culture collection of the Grupo de Micobactérias, Unidade de Microbiologia Médica, of the Instituto de Higiene e Medicina Tropical (IHMT), Universidade NOVA de Lisboa (UNL). The panel of M. tuberculosis strains studied was selected according to their susceptibility pattern and the presence of the most common mutations associated with resistance to isoniazid and rifampicin in order to include susceptible, isoniazid monoresistant, rifampicin monoresistant, MDR, and XDR. Informed consent was not required for this study since it is a retrospective study from which all patient identification was unlinked from the results, and no patient information was collected. M. tuberculosis H37Rv ATCC27294 T was obtained from the American Type Culture Collection (Manassas, VA, USA) and was included as control strain.
Antimicrobials and Reagents
The antibiotics isoniazid and rifampicin, the efflux inhibitors verapamil and thioridazine, the efflux substrate ethidium bromide (EtBr), Tween 80, phosphate buffered saline (PBS), dimethyl sulfoxide (DMSO), and glucose, were obtained from Sigma-Aldrich (St. Louis, MO, USA). Rifampicin was prepared in DMSO, while the remaining drugs were prepared in sterile deionized water. The stock solutions were aliquoted and stored at −20 • C and the working solutions freshly prepared on the day of the experiment. The lyophilized drugs (BACTEC MGIT 960 SIRE and PZA kits; SIRE, streptomycin, isoniazid, rifampicin, ethambutol; PZA, pyrazinamide) used in the standard susceptibility testing were purchased from Becton Dickinson (Diagnostic Systems, Sparks, MD, USA) and the stock solutions prepared as per the manufacturer's instructions. BD Difco Middlebrook 7H9, BD BBL OADC (oleic acid/albumin/dextrose/catalase) supplement and the Mycobacteria Growth Indicator Tubes (MGITs) were from Becton Dickinson.
Susceptibility Testing
Growth of the Strains
For first-line susceptibility testing, MIC determination, and synergism assays, the M. tuberculosis strains were inoculated in MGITs tubes supplemented with 10% OADC and incubated at 37 • C in the BACTEC MGIT 960 (MGIT 960) system until they reached 100-200 growth units (GUs) and were used directly for testing. Cultures with 200 < GU < 2000 were diluted to 100-200 GU with a sterile saline solution and used for testing. Growth of the cultures was monitored with the Epicenter V5.80A software equipped with the TB eXIST module (Becton Dickinson).
First-Line Drug Susceptibility Testing
The MGIT 960 was used for first-line drug susceptibility testing according to the manufacturer's instructions. The MGIT tubes were inoculated with 0.8 mL of OADC, 0.1 mL of the antibiotic at the critical concentrations (0.1 µg/mL for isoniazid, 1 µg/mL for rifampicin, 1 µg/mL for streptomycin, 5 µg/mL for ethambutol, 100 µg/mL for pyrazinamide) and 0.5 mL of the suspension of the strain. For preparation of the drug-free proportional control, the strain suspension was diluted 1:100 (1:10 for PZA) with a sterile saline solution and 0.5 mL inoculated in the tube. The results were interpreted as follows: if the GU of the tubes containing the drug were >100 when the proportional control reached 400 GU, they were considered to be resistant to the respective concentration. If the GU of the tube containing the drug was <100, they were considered susceptible [39] .
MIC Determination of Antibiotics and Efflux Inhibitors
MIC determination of the antibiotics and efflux inhibitors was performed within the MGIT 960 and the Epicenter V5.80A/TB eXIST software. The inoculum of the strains and the MGIT tubes were prepared as described above. At the time of testing, two-fold serial dilutions were prepared to achieve the desired concentrations and 0.1 mL added to the corresponding drug-containing tubes. For the proportion testing it was prepared two drug-free controls: the absolute control (1:1) and the proportional control (1:100). The MIC was considered as the lowest concentration with GU < 100 when the drug-free proportional control tube reached a GU value of 400.
Quantitative Drug Susceptibility Testing of Antibiotics in Presence and Absence of Inhibitors
Quantitative drug susceptibility testing of rifampicin and isoniazid conducted using the MGIT 960 and the Epicenter V5.80A/TB eXIST. Isoniazid was tested at 0.1, 1, 3, and 10 µg/mL and rifampicin at 1, 4, and 20 µg/mL. For the quantification of the antibiotic resistance levels of each strain, the results were interpreted as per Cambau et al. [38] as follows: isoniazid low-level resistance when resistant (R) at 0.1 and susceptible (S) at 1 µg/mL; isoniazid high-level resistance when R ≥ 1; rifampicin low-level resistance when R at 4 and S at 20 µg/mL; rifampicin high-level resistance when R ≥ 20 µg/mL. The preparation of the drug containing tubes and controls was done as described above. For the susceptibility testing for the antibiotics in the presence of the inhibitors, the tubes containing 0.1 mL of the antibiotics at the desired concentrations were inoculated with 0.1 mL of the inhibitor to a final concentration of 1/2 or 1/4 their MIC, depending on the strain. These concentrations were selected in order to not compromise the growth of the strains following the protocol described above. The resistance levels for each combination (antibiotic + efflux inhibitor) were quantified as describe above.
Ethidium Bromide Real-Time Fluorometry
To detect the accumulation and extrusion of ethidium bromide, a common substrate of several efflux pumps, we applied a real-time fluorometric method using a Rotor-Gene 3000 thermocycler (Corbett Research, Sydney, Australia) [31, 40] . The assays were performed as previously described [19] . The strains were grown in 10 mL of MB7H9 medium, 10% OADC, and 0.05% Tween 80, at 37 • C, without stirring, until they reached an approximate OD 600 of 0.8. The cells were collected by centrifugation at 2940× g, for 3 min at room temperature. The supernatant was discarded, the pellet washed, resuspended in PBS, and centrifuged as before. This procedure was performed twice.
For the ethidium bromide accumulation assays, the washed cells were re-suspended in PBS and the OD 600 adjusted to 0.8. To determine the equilibrium concentration, i.e., the lowest concentration of ethidium bromide that causes accumulation, 50 µL of the cell suspension was added to 0.2 mL tubes containing different concentrations of ethidium bromide that ranged from 0.125 to 3 µg/mL. The final OD 600 of the bacterial suspension in the assay was 0.4. The assays were conducted at 37 • C in a Rotor-Gene 3000, and the fluorescence of ethidium bromide was measured (530/585 nm) at the end of each cycle of 60 s, for 60 min. After this, the effect of the efflux inhibitors verapamil and thioridazine on the accumulation of ethidium bromide was evaluated for each strain. These assays were performed like described above with each efflux inhibitor at 1/2 or 1/4 of the MIC and ethidium bromide at the higher concentration that does not cause accumulation determined for each strain. To quantify the effect of the inhibitors in the accumulation of ethidium bromide, for each strain we determined the relative final fluorescence (RFF) as previously described [41] . RFF values above 0 indicated that cells accumulate more ethidium bromide under the condition used than the non-treated cells. Each assay was performed in triplicate and the results presented correspond to the average of three independent assays (±SD).
For the efflux assays, the washed cells were resuspended in PBS and the OD 600 adjusted to 0.4. The ethidium bromide loaded cells were prepared by incubating the cell suspension in the presence of the highest concentration of ethidium bromide that does not cause accumulation and verapamil at 1/2 (or 1/4) of the MIC at room temperature during 60 min. After EtBr accumulation, the cells were collected by centrifugation at 2940× g during 3 min, room temperature, and resuspended in PBS to an OD 600nm of 0.8. Then, 50 µL of the suspension was added to 0.2 mL tubes containing (1) PBS only; (2) PBS plus glucose, to a final concentration of 0.4%; (3) verapamil only; and (4) glucose to a final concentration of 0.4% plus verapamil. The final OD 600 of the bacterial suspension in the assay was 0.4. The fluorescence of ethidium bromide was measured, as described above. The fluorescence was acquired first, at the end of 15 s and at the end of every 30 s during the following 30 min. The efflux activity was quantified by comparing the fluorescence data obtained for the cells under conditions that allow maximum efflux (incubation at 37 • C in the presence of glucose and absence of a compound) against the data from the control tube that contains the ethidium-bromide-loaded cells under conditions that inhibit the efflux (with a compound and absence of glucose). The normalized data (Y, fluorescence vs. X, time) was plotted using GraphPad Prism (GraphPad Software, La Jolla, CA, USA) [42] . Ethidium bromide efflux curves were fitted using a single exponential decay equation as follows: Y = (Y0 − Plateau) * exp(−K * X) + Plateau, where X is the time, Y is the ethidium bromide efflux that starts at Y 0 and decays to the plateau in one phase; the plateau is Y at infinite times. The plateau has the same units as Y and the K or slope is the efflux rate constant.
Genotypic Characterization of the Strains
(i) DNA extraction: Genomic DNA was extracted using the QIAamp DNA mini kit (QIAGEN, GmbH, Hilden, Germany) according to the manufacturer's instructions. (ii) Screening of mutations: The most common mutations in rpoB, katG, and the inhA promoter were screened using the system Genotype MTBDRplus V2 (Hain Lifescience GmbH, Nehren, Germany) according to the manufacturer's instructions. (iii) DNA sequencing: The analysis of internal fragments of the genes katG, inhA, and rpoB was performed according to Machado et al. [43] . (iv) Strain typing: Spoligotyping was performed as previously described [44] . Detection of the hybridization patterns was carried out using the ECL Chemiluminescence Detection System (GE Healthcare, Cleveland, OH, USA).
Statistical Analysis
Statistical analysis was carried out using the Student's t-test. A * p value < 0.05 was considered statistically significant and highly significant when ** p < 0.01 and *** p < 0.001 (two-tailed test).
Conclusions
The acquisition of drug resistance by the M. tuberculosis strains is frequently associated with a decreased in the bacterial fitness and reduced transmissibility. Nevertheless, M. tuberculosis can evolve and adapt to reduce the biological cost of MDR by the acquisition of compensatory mechanisms to ameliorate the cost of its resistance, allowing its survival and spread in the population. The findings gathered in this study emphasize the contribution of efflux activity in M. tuberculosis towards adaptive evolution. The overactivity of efflux pumps should be considered when studding the impact of MDR in the transmission dynamics and virulence of M. tuberculosis clinical strains. Drug resistance mediated by efflux has become an important issue since it helps the bacteria to survive in the presence of antimicrobial compounds. In this sense, the potential use of efflux inhibitors in combination with antibiotics may be valuable as adjunct for a combined therapeutic approach. The overactivity of efflux pumps can influence the bacterial dynamics within the population in the presence of antibiotic pressure, until mutations in the drug targets arise and establish in the population [19] . The final resistance level is a combination between the efflux of the drug and the presence of the mutations [18] . This work complemented our previous findings now demonstrating how efflux activity modulates the levels of drug resistance between monoresistant and M/XDR M. tuberculosis clinical strains allowing the bacteria to survive for longer periods in the presence of noxious compounds.
Further studies into the mechanisms of drug resistance that alleviate the biological cost of drug resistance will help to better understand the emergence, epidemiological success, and dissemination of antimicrobial resistance in the clinical setting and also aid in its management and prevention.
